Research
Hormonal
In nonobese humans, there is a weak inverse correlation between serum resistin and insulin sensitivity, but this association disappears when adjusting for body fat percentage.
In lean individuals, higher resistin levels are weakly associated with lower insulin sensitivity, but this is likely driven by body fat levels rather than resistin itself. Adjusting for body fat eliminates this link.
GoodQualifiesMEDIUM confidence
Serum resistin was, however, inversely related to insulin sensitivity in nonobese subjects only (r = -0.35; P = 0.05), although this association was lost after adjusting for percent body fat.
Why this rating
Same high-quality methodology as N1, but the finding is statistically marginal (P=0.05) and vanishes with covariate adjustment.
Source
Relationship between Serum Resistin Concentrations and Insulin Resistance in Nonobese, Obese, and Obese Diabetic Subjects
Leonie K. Heilbronn et al. · The Journal of Clinical Endocrinology & Metabolism · 2004
DOI 10.1210/jc.2003-031410
cross_sectional · n=90Cited 307×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Serum resistin concentrations are not significantly correlated with insulin sensitivity (glucose disposal rate) in obese or obese diabetic humans, indicating resistin is unlikely to be a major mediator of insulin resistance in these populations.Good
- Serum resistin levels are directly correlated with resistin mRNA expression in abdominal subcutaneous adipose tissue, suggesting adipose tissue is a source of circulating resistin.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →